Revium Rx.

What they do

Revium Rx is a pre-clinical stage biopharmaceutical company developing innovative nanoparticle-based therapies using lipid-based delivery systems. Its programs focus on antimicrobial resistance, solid tumors, and a novel vaccination approach. The company has not generated any revenue from product sales and has not yet clinically tested its candidates in the US or elsewhere.

Revenue drivers

• Nano-Mupirocin — The most advanced program, aimed at antibiotic-resistant infections; a clinical batch has been manufactured and released, but no revenue is expected until commercialization, which is years away.
• Solid tumor therapies — Early-stage lipid-based platform candidates for solid tumors; no clinical testing yet and no revenue.
• Novel vaccination approach — An exploratory program using the lipid-based platform; no revenue or development milestones reported.

Recent performance

For fiscal year 2025, the company reported a net loss of $13.4 million and diluted EPS of -$0.22. As of June 30, 2026, the company had cash and equivalents of $842,000, total assets of $7.1 million, total liabilities of $1.6 million, and shareholder equity of $5.5 million. The company has not generated any revenues from product sales to date. In the latest quarter, management highlighted progress on the Nano-Mupirocin program, including manufacturing and release of a clinical batch by WuXi AppTec and completion of a GLP toxicology study, which is now in histopathological analysis.

Strategy

The company's strategy is to develop lipid-based nanoparticle therapies that enhance delivery, control release, and improve the therapeutic index of established drugs, targeting high unmet needs like antimicrobial resistance and solid tumors. It leverages external manufacturing and contract research organizations, as evidenced by WuXi AppTec's role, and internal expertise in nano-medicine. The company also plans to conduct clinical trials to validate its preclinical observations, though it acknowledges no assurance these will replicate in humans.

Risks

• No revenue and limited cash — The company has no product revenue and only $842,000 in cash as of June 30, 2026, which is insufficient to fund long-term operations without additional financing.
• Pre-clinical stage with no clinical data — All product candidates are pre-clinical and have not been tested in humans, so there is no evidence they will be safe or effective in clinical trials.
• Dependence on third-party manufacturing — The Nano-Mupirocin program relies on WuXi AppTec for clinical batch manufacturing, and any disruption or quality issue could delay development.
• Regulatory and development delays — The GLP toxicology study is still in histopathological analysis, and regulatory submissions and clinical initiation are subject to uncertainty and potential delays.

Outlook

Management expects to continue incurring substantial R&D expenses for the next several years, but cannot estimate costs or timelines. Near-term priorities include completing histopathological analysis of the GLP toxicology study and preparing regulatory submissions to support clinical initiation of the Nano-Mupirocin program. The company's ability to execute depends on raising additional capital, which is not assured.